Wedbush reiterates Outperform rating on Sutro Biopharma, $60 price target

SUTRO BIOPHARMA, INC. (STRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study – Encouraging early clinical activity including confirmed and ongoing unconfirmed partial responses with favorable tolerability, and pharmacokinetics (PK

Lockheed Martin (LMT) plans to invest $300M to expand its Grand Prairie facility by 185,000 sq ft, adding 2,000 jobs in Texas and 4,000 nationwide. The expansion aims to boost munitions production, with Hadrian's automated system expected to speed up manufacturing. Lockheed is committing $8B-$9B through 2030 to scale production.

Kimco Realty (KIM) raised its quarterly dividend 12% to $0.28 per share, while Simon Property Group (SPG) increased its dividend 4.7% to $2.25 per share. Kimco yields 5.1% and Simon yields 4.5%. Simon's AFFO payout ratio is 76% and Kimco's is 80%. Kimco has higher debt at 6.1x net debt to EBITDA compared to Simon's 5.5x.

Vogenx, Inc. (VOGX) began a Phase 2b trial for mizagliflozin in post-bariatric hypoglycemia, enrolling 36 U.S. patients. The 28-day study tests 5 mg and 10 mg doses, with hypoglycemic events as the primary endpoint.

Hyster-Yale, Inc. (HY) named Matthew J. Cornell as Senior Vice President and CFO, starting Nov. 1, 2026. He previously held senior roles at Stanley Black & Decker. The company expects this change to impact capital allocation and operational execution.

Crescent Biopharma (CBIO) announced enrollment in CR-001 chemo combination cohorts and IND allowance for CR-002, with initial data expected in 2027. The company completed CR-001 monotherapy dose escalation and expects initial monotherapy data from over 125 patients and ORR in up to 12 1L NSCLC patients by Q1 2027. The FDA allowed IND for CR-002, with a global Phase 1/2 APOLLO trial to start Q4 2026 and initial data anticipated in H2 2027.